New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2013
11:38 EDTGGB, PSTI, AWAY, EBIX, DDSHigh option volume stocks: GGB PSTI AWAY EBIX DDS
News For GGB;PSTI;AWAY;EBIX;DDS From The Last 14 Days
Check below for free stories on GGB;PSTI;AWAY;EBIX;DDS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 8, 2014
05:43 EDTPSTIPluristem Therapeutics advances to second cohort in PLX-PAD cells Phase I trial
Pluristem Therapeutics announced that its licensee, United Therapeutics Corporation, has completed the dosing of the first cohort of patients in its Phase I study using Pluristem's PLacental eXpanded, or PLX-PAD, cells in patients diagnosed with pulmonary arterial hypertension, or PAH. PAH, with a global market estimated at approximately $3B, is characterized by abnormally high blood pressure in the arteries of the lungs; it can disrupt lung and heart function, leading to debilitating conditions such as heart failure. The Phase I study, being conducted in Australia, is an open-label, dose-escalation study designed to enroll 9 patients diagnosed with PAH. The first cohort of 3 patients has received 0.5M PLX cells per kilogram body weight. An independent Data Safety Monitoring Board recommended advancement to the second cohort. The second cohort will receive 1M cells per kilogram, while the third cohort is planned to be administered 2M cells per kilogram. The primary endpoint of the study is the safety of PLX-PAD cells, which will be evaluated at 12 weeks and one year after dosing. Secondary efficacy endpoints are to be measured at six weeks post-treatment in order to assess changes in the ability to exercise, disease severity and cardio-respiratory function; measures include six-minute walk distance and cardio-pulmonary hemodynamic parameters evaluated via right heart catheterization and echocardiogram.
September 2, 2014
07:33 EDTEBIXEbix purchases new buildings in India
Ebix announced that it has completed the purchase of two new buildings in Noida, India, in the Export Processing Zone of the Govt. of India. The company paid for the purchase using its own cash reserves in June. The company also announced that it has received a 100 percent tax-exempt status for these new buildings, until 2019, under the Software Export Zone, or SEZ, Act of the Govt. of India, after which the company is entitled to a 50% tax-free status in India until 2024. With this new purchase, the company now has a total of 10 offices in India spread across Noida, Chennai, Coimbatore, Nagpur, Hyderabad and Bangalore. Ebix presently employs in excess of 1,200 employees in India. These buildings will facilitate the Company's near- and long-term growth and acquisition plans and the associated need for offshore development and BPO resources.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use